19 related articles for article (PubMed ID: 16416012)
1. The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis.
Basnet S; Zhang ZY; Liao WQ; Li SH; Li PS; Ge HY
J Cancer; 2016; 7(9):1105-13. PubMed ID: 27326254
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.
Madar S; Harel E; Goldstein I; Stein Y; Kogan-Sakin I; Kamer I; Solomon H; Dekel E; Tal P; Goldfinger N; Friedlander G; Rotter V
PLoS One; 2013; 8(4):e61353. PubMed ID: 23630584
[TBL] [Abstract][Full Text] [Related]
3. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front.
De Wever O; Pauwels P; De Craene B; Sabbah M; Emami S; Redeuilh G; Gespach C; Bracke M; Berx G
Histochem Cell Biol; 2008 Sep; 130(3):481-94. PubMed ID: 18648847
[TBL] [Abstract][Full Text] [Related]
4. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
7. Circulating vascular endothelial growth factor in patients with colorectal cancer.
Fujisaki K; Mitsuyama K; Toyonaga A; Matsuo K; Tanikawa K
Am J Gastroenterol; 1998 Feb; 93(2):249-52. PubMed ID: 9468253
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
9. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients.
Famulski W; Sulkowska M; Wincewicz A; Kedra B; Pawlak K; Zalewski B; Sulkowski S; Koda M; Baltaziak M
Neoplasma; 2006; 53(1):43-8. PubMed ID: 16416012
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive molecular markers in colorectal carcinoma.
Bendardaf R; Lamlum H; Pyrhönen S
Anticancer Res; 2004; 24(4):2519-30. PubMed ID: 15330208
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
